S&P 500   3,355.41 (+1.73%)
DOW   27,672.56 (+1.83%)
QQQ   276.18 (+1.70%)
AAPL   114.47 (+1.95%)
MSFT   209.49 (+0.80%)
FB   256.62 (+0.71%)
GOOGL   1,461.17 (+1.54%)
AMZN   3,158.26 (+2.04%)
TSLA   418.81 (+2.82%)
NVDA   516.21 (+0.24%)
BABA   276.11 (+1.85%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.94 (+1.13%)
T   28.62 (+2.07%)
F   6.72 (+3.23%)
ACB   4.89 (-3.17%)
GILD   62.94 (+1.11%)
NFLX   486.86 (+0.82%)
DIS   126.33 (+1.88%)
BAC   24.25 (+3.24%)
BA   165.46 (+6.04%)
S&P 500   3,355.41 (+1.73%)
DOW   27,672.56 (+1.83%)
QQQ   276.18 (+1.70%)
AAPL   114.47 (+1.95%)
MSFT   209.49 (+0.80%)
FB   256.62 (+0.71%)
GOOGL   1,461.17 (+1.54%)
AMZN   3,158.26 (+2.04%)
TSLA   418.81 (+2.82%)
NVDA   516.21 (+0.24%)
BABA   276.11 (+1.85%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.94 (+1.13%)
T   28.62 (+2.07%)
F   6.72 (+3.23%)
ACB   4.89 (-3.17%)
GILD   62.94 (+1.11%)
NFLX   486.86 (+0.82%)
DIS   126.33 (+1.88%)
BAC   24.25 (+3.24%)
BA   165.46 (+6.04%)
S&P 500   3,355.41 (+1.73%)
DOW   27,672.56 (+1.83%)
QQQ   276.18 (+1.70%)
AAPL   114.47 (+1.95%)
MSFT   209.49 (+0.80%)
FB   256.62 (+0.71%)
GOOGL   1,461.17 (+1.54%)
AMZN   3,158.26 (+2.04%)
TSLA   418.81 (+2.82%)
NVDA   516.21 (+0.24%)
BABA   276.11 (+1.85%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.94 (+1.13%)
T   28.62 (+2.07%)
F   6.72 (+3.23%)
ACB   4.89 (-3.17%)
GILD   62.94 (+1.11%)
NFLX   486.86 (+0.82%)
DIS   126.33 (+1.88%)
BAC   24.25 (+3.24%)
BA   165.46 (+6.04%)
S&P 500   3,355.41 (+1.73%)
DOW   27,672.56 (+1.83%)
QQQ   276.18 (+1.70%)
AAPL   114.47 (+1.95%)
MSFT   209.49 (+0.80%)
FB   256.62 (+0.71%)
GOOGL   1,461.17 (+1.54%)
AMZN   3,158.26 (+2.04%)
TSLA   418.81 (+2.82%)
NVDA   516.21 (+0.24%)
BABA   276.11 (+1.85%)
CGC   14.29 (+0.85%)
GE   6.24 (+2.13%)
MU   49.13 (-0.02%)
AMD   78.94 (+1.13%)
T   28.62 (+2.07%)
F   6.72 (+3.23%)
ACB   4.89 (-3.17%)
GILD   62.94 (+1.11%)
NFLX   486.86 (+0.82%)
DIS   126.33 (+1.88%)
BAC   24.25 (+3.24%)
BA   165.46 (+6.04%)
Log in
NASDAQ:LTRN

Lantern Pharma Stock Forecast, Price & News

$20.20
+1.84 (+10.02 %)
(As of 09/28/2020 01:47 PM ET)
Add
Compare
Today's Range
$19.15
Now: $20.20
$20.20
50-Day Range
$10.78
MA: $15.10
$19.24
52-Week Range
$10.40
Now: $20.20
$19.50
Volume920 shs
Average Volume45,692 shs
Market Capitalization$125.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.
Read More
Lantern Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.03 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LTRN
CUSIPN/A
CIKN/A
Phone972-277-1136

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees4
Market Cap$125.60 million
Next Earnings Date10/29/2020 (Estimated)
OptionableNot Optionable
$20.20
+1.84 (+10.02 %)
(As of 09/28/2020 01:47 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LTRN News and Ratings via Email

Sign-up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lantern Pharma (NASDAQ:LTRN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Lantern Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Lantern Pharma
.

When is Lantern Pharma's next earnings date?

Lantern Pharma is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Lantern Pharma
.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) posted its quarterly earnings results on Thursday, July, 30th. The company reported ($0.31) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.06.
View Lantern Pharma's earnings history
.

What price target have analysts set for LTRN?

3 brokerages have issued twelve-month target prices for Lantern Pharma's stock. Their forecasts range from $24.00 to $25.00. On average, they anticipate Lantern Pharma's stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price.
View analysts' price targets for Lantern Pharma
.

Who are some of Lantern Pharma's key competitors?

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include NVIDIA (NVDA), Shopify (SHOP), Adobe (ADBE), Oroplata Resources (ABML), Bellus Health (BLU), Capricor Therapeutics (CAPR), Ciena (CIEN), Editas Medicine (EDIT), Eros International (EROS) and ETHEREUM CLASSI/SHS (ETCG).

Who are Lantern Pharma's key executives?

Lantern Pharma's management team includes the following people:
  • Mr. Panna Sharma, Pres, CEO & Director (Age 49, Pay $331.92k)
  • Mr. David R. Margrave, CFO & Sec. (Age 59, Pay $10k)
  • Dr. Peter L. Nara, Co-Founder
  • Dr. Kishor Gopaldas Bhatia Ph.D., Chief Scientific Officer & Scientific Consultant (Age 65)

When did Lantern Pharma IPO?

(LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

What is Lantern Pharma's stock symbol?

Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN."

When does the company's lock-up period expire?

Lantern Pharma's lock-up period expires on Tuesday, December 8th. Lantern Pharma had issued 1,750,000 shares in its IPO on June 11th. The total size of the offering was $26,250,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Lantern Pharma?

Shares of LTRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lantern Pharma's stock price today?

One share of LTRN stock can currently be purchased for approximately $20.20.

How big of a company is Lantern Pharma?

Lantern Pharma has a market capitalization of $125.60 million. Lantern Pharma employs 4 workers across the globe.

What is Lantern Pharma's official website?

The official website for Lantern Pharma is www.lanternpharma.com.

How can I contact Lantern Pharma?

Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The company can be reached via phone at 972-277-1136 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.